<div id="readability-page-1"><p>PureTech Health plc (LON:PRTC - Get Free Report)'s share price traded down 9.2% on Tuesday . The company traded as low as GBX 126 and last traded at GBX 126. 1,066,844 shares traded hands during mid-day trading, a decline of 15% from the average session volume of 1,249,921 shares. The stock had previously closed at GBX 138.80.</p><div><p><span></span><span>Get <strong>PureTech Health</strong> alerts:</span></p></div><h2>PureTech Health Stock Performance</h2><p>The company has a debt-to-equity ratio of 6.33, a current ratio of 6.59 and a quick ratio of 2.51. The stock has a market capitalization of £306.71 million, a PE ratio of -2.74 and a beta of 1.35. The stock has a 50 day moving average of GBX 121.85 and a two-hundred day moving average of GBX 125.88. </p><h2>PureTech Health Company Profile</h2> (Get Free Report)<p>PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than PureTech Health</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PureTech Health Right Now?</h2><p>Before you consider PureTech Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.</p><p>While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRTC

PRTCY

<p>PureTech Health (LON:PRTC) shares fell 9.2% to GBX 126, with 1,066,844 shares traded, a 15% decline from average volume. The company has a market cap of £306.71 million, a PE ratio of -2.74, and a debt-to-equity ratio of 6.33. Analysts currently rate the stock as a Buy, but it is not among the top recommendations. PureTech focuses on developing treatments for nervous, gastrointestinal, and immune system disorders.</p>

PureTech Health (LON:PRTC) Shares Down 9.2% - Time to Sell?